• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Section Contents Menu

Enforcement Actions

Van Heel, David B. 08-May-06

Department of Health and Human Services' logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration

 

Minneapolis District Office
Central Region
212 Third Avenue South
Minneapolis, MN 55401
Telephone: (612) 758-7132
FAX: (612) 334-4142




May 8, 2006

WARNING LETTER

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Refer to MIN 06 - 25

David B. Van Heel
Owner
1603 145th Street
Swanville, MN 56382-4550

Dear Mr. Van Heel:

An investigation of your dairy operation located at Swanville, Minnesota, was conducted by an investigator from the Minnesota Department of Agriculture, acting on behalf of the U.S. Food and Drug Administration (FDA), on January 25, 2006. This investigation confirmed that you offered an animal for sale for slaughter as food that was adulterated under sections 402(a)(2)(C)(ii) [21 U.S.C. 342(a)(2)(C)(ii)] and 402(a)(4) [21 U.S.C. 342(a)(4)] of the Federal Food, Drug, and Cosmetic Act (the Act). The inspection also revealed that you caused the new animal drugs florfenicol, penicillin G procaine-dihydrostreptomycin sulfate, penicillin G procaine, and gentamicin to become adulterated within the meaning of section 501(a)(5) [21 U.S.C. 351(a)(5)] and unsafe under section 512 of the Act [21 U.S.C. 360b]. You can find the Act and its associated regulations on the Internet through links on the FDA's web page at www.fda.gov.

On or about July 11, 2005, you consigned a dairy cow, identified with back tag 6480, for slaughter as food at [redacted]. On or about July 12, 2005, this animal was slaughtered at [redacted]. The United States Department of Agriculture Food Safety and Inspection Service (USDA/FSIS) analysis of tissue samples collected from that animal identified the presence of gentamicin in kidney tissue. No tolerance has been established for residues of gentamicin in the edible tissues of cattle as codified in Title 21, Code of Federal Regulations, 556.300.(21 CFR 556.300). The presence of this drug in edible tissue from this animal causes the food to be adulterated within the meaning of section 402(a)(2)(C)(ii) of the Act [21 U.S.C. 342 (a) (2) (C) (ii)].

Our investigation also found that you hold animals under conditions that are so inadequate that medicated animals bearing potentially harmful drug residues are likely to enter the food supply. You lack an adequate system to ensure that, animals medicated by you have been withheld from slaughter for appropriate periods of time to permit depletion of potentially hazardous residues of drugs from edible tissues. For example, you failed to maintain treatment records and you failed to maintain an adequate inventory system for determining the quantities of drugs to medicate your animals. Food from animals held under such conditions is adulterated within the meaning of section 402(a)(4) of the Act [21 U.S.C. 342(a)(4)].

In addition, you adulterated florfenicol, penicillin G procaine-dihydrostreptomycin sulfate, penicillin G procaine, and gentamicin within the meaning of section 501(a)(5) of the Act [21 U.S.C. 351(a)(5)] when you failed to use these drugs in conformance with their approved labeling. "Extralabel use," i.e., the actual or intended use of a drug in an animal in a manner that is not in accordance with the approved labeling, is only permitted if the use is by or on the lawful order of a licensed veterinarian within the context of a valid veterinarian/client/patient relationship. The extralabel use of approved veterinary or human drugs must comply with sections 512(a)(4) and 512(a)(5) of the Act arid 21 CFR 53301. Our investigation found that your extralabel use of florfenicol, penicillin G procaine-dihydrostreptomycin sulfate, penicillin G procaine, and gentamicin failed to comply with these requirements.

For example, you administered the florfenicol, penicillin G procaine-dihydrostreptomycin sulfate, and gentarnicin without following the animal class set forth in the approved labeling. In addition, you administered penicillin G procaine without following the dosage level of treatment set forth in the approved labeling, and you did so without the supervision of a licensed veterinarian, in violation of 21 CFR 530.11(a). Furthermore, your extralabel use of gentamicin resulted in an illegal drug residue, in violation of 21 CFR 530.11(c). Because your extralabel use of these drugs was not in compliance with 21 CFR 530, your use caused the drugs to be unsafe under section 512(a) of the Act [21 U.S .C. 360b(a)] and your use caused them to be adulterated within the meaning of section 501(a)(5) of the Act [21 U.S.C. 351(a)(5)].

The above is not intended to be an all inclusive list of violations. As a producer of animals offered for use as food, you are responsible for ensuring that your overall operation and the food you distribute are in compliance with the law.

You should take prompt action to correct the above violations and to establish procedures whereby such violations do not recur. Failure to do so may result in regulatory action without further notice such as seizure and/or injunction.

You should notify this office in writing of the steps you have taken to bring your firm into compliance with the law within fifteen (15) working days of receiving this letter. Your response should include each step that has been taken or will be taken to correct the violations and prevent their recurrence. If corrective action cannot be completed within fifteen (15) working days, state the reason for the delay and the time frame within which the corrections will be completed. Please include copies of any available documentation demonstrating that corrections have been made.

Your written response should be sent to Brian D. Garthwaite, Ph.D., Compliance Officer, at the address located on the letterhead. If you have any questions about this letter, please contact Dr. Garthwaite at (612) 758-7132.

Sincerely,

/S/

W. Charles Becoat
Director
Minneapolis District